Crossmark

Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study

Crossref DOI link: https://doi.org/10.1186/s12933-018-0663-6

Published Online: 2018-01-24

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chan, Cheng-Wei

Yu, Chu-Leng

Lin, Jiunn-Cherng

Hsieh, Yu-Cheng https://orcid.org/0000-0001-6218-7139
Lin, Che-Chen

Hung, Chen-Ying

Li, Cheng-Hung

Liao, Ying-Chieh

Lo, Chu-Pin

Huang, Jin-Long

Lin, Ching-Heng

Wu, Tsu-Juey
Funding

Funding for this research was provided by:

Taichung Veterans General Hospital (TCVGH-NHRI10603)

Taichung Veterans General Hospital (TCVGH-1067310C)

Taichung Veterans General Hospital (TCVGH-FCU1068205)

Taichung Veterans General Hospital (TCVGH-YM1060201)

Taichung Veterans General Hospital (TCVGH-VTA106PREM1)

Taichung Veterans General Hospital (TCVGH-1043109C)

Taichung Veterans General Hospital (TCVGH-1053108C)

Taichung Veterans General Hospital (TCVGH-VHCY1068606)

Taichung Veterans General Hospital (TCVGH-1033103C)

Taichung Veterans General Hospital (TCVGH-1033105C)

National Science Council, Taiwan (102-2314-B-075A-009-MY2)

National Science Council, Taiwan (104-2314-B-367-001)

National Science Council, Taiwan (105-2314-B-367-001-MY3)
License Information

Text and Data Mining valid from 2018-01-24

Version of Record valid from 2018-01-24
More Information

Article History

Received: 31 October 2017

Accepted: 15 January 2018

First Online: 24 January 2018

Document is current

Any future updates will be listed below